Enhanced radiation response through directed molecular targeting approaches

被引:9
作者
Collis, SJ
DeWeese, TL [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Urol, Baltimore, MD 21231 USA
关键词
ionizing radiation; gene therapy; radiosensitivity; molecular targeting; DNA damage and repair;
D O I
10.1023/B:CANC.0000031767.30730.d1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In both the pre- and post-human genome sequencing eras, there has been an increase in the understanding of the molecular mechanisms influencing cellular sensitivity to DNA damaging agents such as ionizing radiation. Out of this work have arisen many cellular factors that could be specifically targeted, at the molecular level, to alter the functionality of a single protein or pathway involved in the response to radiation damage as a means to increase cell killing following radiation treatment. As such, there are many promising new combination radio-gene therapy approaches being developed and assessed in pre- clinical and clinical studies for several different malignancies. Combination of such modalities aims to increase the therapeutic index, giving rise to increased tumor cell killing with a simultaneous reduction in normal cell toxicity. Restricted delivery and/or targeting modalities combined with conformal radiotherapy regimes could provide significant local control of tumors, impeding their development into metastatic disease, which poses a greater challenge for palliative and curative treatments. This review will summarize current and novel gene therapy strategies that are being developed aimed at enhancing the effects of radiotherapy through the use of directed molecular targeting approaches.
引用
收藏
页码:277 / 292
页数:16
相关论文
共 145 条
[1]   Lentiviral-mediated RNA interference [J].
Abbas-Terki, T ;
Blanco-Bose, W ;
Déglon, N ;
Pralong, W ;
Aebischer, P .
HUMAN GENE THERAPY, 2002, 13 (18) :2197-2201
[2]   A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme [J].
Amado, RG ;
Mitsuyasu, RT ;
Symonds, G ;
Rosenblatt, JD ;
Zack, J ;
Sun, LO ;
Miller, M ;
Ely, J ;
Gerlach, W .
HUMAN GENE THERAPY, 1999, 10 (13) :2255-+
[3]   Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas [J].
Angèle, S ;
Treilleux, I ;
Brémond, A ;
Tanière, P ;
Hall, J .
HISTOPATHOLOGY, 2003, 43 (04) :347-353
[4]   Survivin as a radioresistance factor in pancreatic cancer [J].
Asanuma, K ;
Moriai, R ;
Yajima, T ;
Yagihashi, A ;
Yamada, M ;
Kobayashi, D ;
Watanabe, N .
JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (11) :1204-1209
[5]   A role for survivin in radioresistance of pancreatic cancer cells [J].
Asanuma, K ;
Kobayashi, D ;
Furuya, D ;
Tsuji, N ;
Yagihashi, A ;
Watanabe, N .
JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (09) :1057-1062
[6]  
Belenkov AI, 2002, CANCER RES, V62, P5888
[7]  
Bettinger T, 2001, CURR OPIN MOL THER, V3, P116
[8]   Taking the cell by stealth or storm? Protein Transduction Domains (PTDs) as versatile vectors for delivery [J].
Bogoyevitch, MA ;
Kendrick, TS ;
Ng, DCH ;
Barr, RK .
DNA AND CELL BIOLOGY, 2002, 21 (12) :879-894
[9]   Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase [J].
Boyer, J ;
Rohleder, K ;
Ketner, G .
VIROLOGY, 1999, 263 (02) :307-312
[10]   Antisense drug discovery: Can cell-free screens speed the process? [J].
Branch, AD .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (03) :249-254